Risk of severe diarrhea with dual anti-HER2 therapies: A meta-analysis

Tumor Biology

Volumn 35, Issue 5, 2014, Pages 4077-4085

  Li, Hui ^a   Fu, Wenyan ^a   Gao, Xiang ^b   Xu, Qunfang ^c   Wu, Hua ^c   Tan, Wenlong ^d  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^c BEIJING ELECTRIC POWER HOSPITAL   (China)

^d BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

Breast cancer; Diarrhea; Dual HER2 blockade; Her2; Meta analysis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PERTUZUMAB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE;

ADVERSE OUTCOME; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER THERAPY; CLINICAL EVALUATION; COCHRANE LIBRARY; DIARRHEA; GASTROINTESTINAL TOXICITY; GENETIC HETEROGENEITY; HUMAN; MEDLINE; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT RISK; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; CHEMICALLY INDUCED DISORDER; IMMUNOLOGY; INCIDENCE; PUBLISHING; RISK;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; DIARRHEA; HUMANS; INCIDENCE; PUBLICATION BIAS; QUINAZOLINES; RECEPTOR, ERBB-2; RISK;

EID: 84902951001     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1533-1     Document Type: Article

References (34)

1. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG. Trastuzumab - mechanism of action and use. N Engl J Med. 2007;357(16):1664. doi:10.1056/NEJMc072213. author reply 5-6.
2. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med. 2007;35(1):39-51. doi:10.1056/NEJMra043186.
3. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011;12(3):236- 44. doi:10.1016/S1470-2045(11)70033-X.
4. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659-72. doi:10.1056/NEJMoa052306. (Pubitemid 41464705)
5. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer Jr CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-84. doi:10.1056/NEJMoa052122. (Pubitemid 41464706)
6. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719-26. (Pubitemid 34111379)
7. Nahta R, Esteva FJ. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 2006;8(6):215. doi:10.1186/bcr1612.
8. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006;3(5):269-80. doi: 10.1038/ncponc0509. (Pubitemid 43731112)
9. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275(5308):1943-7. (Pubitemid 27148818)
10. Gustin JP, Cosgrove DP, Park BH. The PIK3CA gene as a mutated target for cancer therapy. Curr Cancer Drug Targets. 2008;8(8):733-40.
11. Mittendorf EA, Liu Y, Tucker SL, McKenzie T, Qiao N, Akli S, et al. A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene. 2010;29(27):3896-907.
12. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004;5(4):317-28. (Pubitemid 38482068)
13. Garrett JT, Sutton CR, Kuba MG, Cook RS, Arteaga CL. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Clin Cancer Res. 2013;19(3):610-9. doi:10.1158/1078-0432.CCR-12-2024.
14. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379(9816):633-40. doi:10.1016/S0140-6736(11)61847-3.
15. Guarneri V, Frassoldati A, Bottini A, Cagossi K, Bisagni G, Sarti S, et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. Journal of Clinical Oncology. 2012;30(16):1989-95.
16. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, LiuMC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25-32. doi:10.1016/S1470-2045(11)70336-9.
17. Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 2012;30(21):2585-92. doi:10.1200/JCO.2011.35.6725.
18. Viele CS. Overviewof chemotherapy-induced diarrhea. Semin Oncol Nurs. 2003;19(4 Suppl 3):2-5.
19. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733-43. doi:10.1056/NEJMoa064320. (Pubitemid 46021510)
20. Kaufman B, Stein S, Casey MA, Newstat BO. Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer. Biologics. 2008;2(1):61-5.
21. Crown JP, Burris 3rd HA, Boyle F, Jones S, Koehler M, Newstat BO, et al. Pooled analysis of diarrhea events in patientswith cancer treated with lapatinib. Breast Cancer Res Treat. 2008;112(2):317-25. doi:10.1007/s10549-007- 9860-9.
22. Ro J, Park S, Kim S, Kim TY, Im YH, Rha SY, et al. Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea. BMC Cancer. 2012;12:322. doi:10.1186/1471-2407-12-322.
23. Muysoms FE, Deerenberg EB, Peeters E, Agresta F, Berrevoet F, Campanelli G et al. Recommendations for reporting outcome results in abdominal wall repair: results of a consensus meeting in Palermo, Italy, 28-30 June 2012. Hernia. 2013. doi:10.1007/s10029-013-1108-5
24. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
25. Robidoux A, Tang G, Rastogi P, Geyer CE, Azar CA, Atkins JN, et al. Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41. J Clin Oncol. 2012;30(18 Suppl):812.
26. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109-19. doi:10.1056/NEJMoa1113216.
27. XiaW, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene. 2002;21(41):6255-63. doi:10.1038/sj.onc.1205794.
28. Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, Bharwani L, et al. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst. 2007;99(9):694-705. doi:10.1093/jnci/djk151. (Pubitemid 47073531)
29. Rimawi MF, Wiechmann LS, Wang YC, Huang C, Migliaccio I, Wu MF, et al. Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res. 2011;17(6):1351-61. doi:10.1158/1078-0432.CCR-10- 1905.
30. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006;66(3):1630-9. doi:10.1158/0008-5472.CAN-05-1182.
31. Nahta R, Yuan LX, Du Y, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther. 2007;6(2):667-74. doi: 10.1158/1535-7163.MCT-06- 0423. (Pubitemid 46332467)
32. Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene. 2009;28(6):803-14. doi:10.1038/onc.2008.432.
33. Cortés J, Baselga J, Petrella T, Gelmon K, Fumoleau P, Verma S, et al. Pertuzumab monotherapy following trastuzumab-based treatment: Activity and tolerability in patients with advanced HER2-positive breast cancer. J Clin Oncol. 2009;27(15S):1022.
34. Gelmon K, Fumoleau P, Verma S, Wardley A, Conte P, Miles D, et al. Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy. J Clin Oncol. 2008;26(15 Suppl):1026.